

Adrian Ciurea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6162032/publications.pdf>

Version: 2024-02-01

59
papers

2,794
citations

304368

22
h-index

182168

51
g-index

60
all docs

60
docs citations

60
times ranked

3231
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
2	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 63-69.	0.5	220
3	Tumor Necrosis Factor $\hat{\pm}$ Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 3096-3106.	6.7	129
4	Impairment of Cd4+ T Cell Responses during Chronic Virus Infection Prevents Neutralizing Antibody Responses against Virus Escape Mutants. <i>Journal of Experimental Medicine</i> , 2001, 193, 297-306.	4.2	86
5	CD4+ T-cell "epitope escape mutant virus selected in vivo. <i>Nature Medicine</i> , 2001, 7, 795-800.	15.2	72
6	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1545-1549.	0.5	71
7	Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 164.	1.6	69
8	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1579-1585.	0.9	63
9	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
10	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 238-241.	0.5	54
11	Impaired response to treatment with tumour necrosis factor $\hat{\pm}$ inhibitors in smokers with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 532-539.	0.5	45
12	Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2118.	2.2	40
13	Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1203-1209.	0.5	37
14	Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 71.	1.6	34
15	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides. <i>Frontiers in Immunology</i> , 2019, 10, 791.	2.2	33
16	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	1.8	33
17	Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 233.	1.6	32
18	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. <i>Immunogenetics</i> , 2001, 53, 185-189.	1.2	30
20	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1410-1418.	0.5	28
21	The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2141-2150.	2.9	25
22	The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. <i>Journal of Autoimmunity</i> , 2017, 83, 122-133.	3.0	25
23	Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and Rheumatologists. <i>Arthritis Care and Research</i> , 2019, 71, 839-851.	1.5	23
24	Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis. <i>RMD Open</i> , 2022, 8, e001949.	1.8	23
25	Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166920.	1.1	22
26	Age at symptom onset in ankylosing spondylitis: is there a gender difference?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1908-1910.	0.5	19
27	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019, 58, 1585-1596.	0.9	19
28	Correlation of findings in clinical and high resolution ultrasonography examinations of the painful shoulder. , 2015, 15, 29-44.		17
29	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , 2020, 15, e0230268.	1.1	17
30	Smoking and spondyloarthritis. <i>Joint Bone Spine</i> , 2013, 80, 234-235.	0.8	15
31	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. <i>PLoS ONE</i> , 2019, 14, e0211554.	1.1	15
32	Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 4598-4608.	0.9	15
33	Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 37, 24-29.	1.1	14
34	Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. <i>Journal of Rheumatology</i> , 2018, 45, 887-894.	1.0	14
35	Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. <i>RMD Open</i> , 2021, 7, e001566.	1.8	14
36	Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 11125.	1.6	13

#	ARTICLE	IF	CITATIONS
37	TNF \pm induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF \pm antibodies. <i>Cardiovascular Research</i> , 2022, 118, 254-266.	1.8	13
38	Treatment with Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Comparison Between Private Rheumatology Practices and Academic Centers in a Large Observational Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 101-105.	1.0	12
39	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.5	11
40	Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. <i>RMD Open</i> , 2022, 8, e002067.	1.8	11
41	HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. <i>PLoS ONE</i> , 2015, 10, e0130811.	1.1	9
42	Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. <i>Rheumatology</i> , 2021, 61, 131-138.	0.9	8
43	Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria. <i>Rheumatology International</i> , 2015, 35, 295-302.	1.5	7
44	Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. <i>PLoS ONE</i> , 2019, 14, e0216746.	1.1	7
45	Impact of discordance between patient \hat{e} ™s and evaluator \hat{e} ™s global assessment on treatment outcomes in 14868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
46	European bio-na \hat{e} ™ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	0.9	7
47	Ossification of the ligamentum flavum. <i>Rheumatology</i> , 2020, 59, 1616-1616.	0.9	6
48	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	0.9	6
49	Response to \hat{e} ™Correspondence on \hat{e} ™Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort \hat{e} ™ by Ruyssen-Witrand $\langle i \rangle$ et al $\langle /i \rangle$. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e33-e33.	0.5	4
50	BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment. <i>Joint Bone Spine</i> , 2013, 80, 433-434.	0.8	2
51	OP0105 \hat{e} ™...HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY. , 2019, , .		2
52	Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors. <i>Arthritis Research and Therapy</i> , 2021, 23, 165.	1.6	2
53	FRI0375 \hat{e} ™...SITE-SPECIFIC EFFECTIVENESS OF TNF INHIBITORS FOR ENTHESITIS IN DMARD-NAIVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		1
54	Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101818.	1.5	1

#	ARTICLE	IF	CITATIONS
55	FRI0144â€¦JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY. , 2019, , .		0
56	OP0221â€¦OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY. , 2019, , .		0
57	OP0031â€¦ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?. , 2019, , .		0
58	Response to: â€œCorrespondence on â€œEffectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohortâ€™ by Micheroli<i>et alâ€™™</i>by Huang<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e227-e227.	0.5	0
59	Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases. RMD Open, 2022, 8, e002439.	1.8	0